Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum.
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections.
Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is reporting results in Q1 2021 from a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.